AB733
Anti-Tamm-Horsfall Glycoprotein Antibody
serum, Chemicon®
製品名
Anti-Tamm-Horsfall Glycoprotein Antibody, serum, Chemicon®
biological source
sheep
antibody form
serum
antibody product type
primary antibodies
clone
polyclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunodiffusion: suitable
immunohistochemistry: suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... UMOD(7369)
Application
IEP: 100 μL antiserum vs. 5 μL uromucoid (50 mg/L)
RID and Rocket RID: 10 μL antiserum/cm2 in gel vs. 5 μL uromucoid (50 mg/L), NT - 1/5
Double diffusion: 10 μL antiserum vs. 3 μL uromucoid (50 mg/L)
*Note: The use of 3% PEG 6000 with 1.2% agarose in a suitable buffer (such as TBE or Tris-barbital pH >8.2) is recommended for the above applications.
Immunohistochemistry
Optimal working dilution must be determined by the end user.
RID and Rocket RID: 10 μL antiserum/cm2 in gel vs. 5 μL uromucoid (50 mg/L), NT - 1/5
Double diffusion: 10 μL antiserum vs. 3 μL uromucoid (50 mg/L)
*Note: The use of 3% PEG 6000 with 1.2% agarose in a suitable buffer (such as TBE or Tris-barbital pH >8.2) is recommended for the above applications.
Immunohistochemistry
Optimal working dilution must be determined by the end user.
Research Category
Inflammation & Immunology
Inflammation & Immunology
Research Sub Category
Immunoglobulins & Immunology
Immunoglobulins & Immunology
This Anti-Tamm-Horsfall Glycoprotein Antibody is validated for use in ID, WB, IH for the detection of Tamm-Horsfall Glycoprotein.
Biochem/physiol Actions
One arc by 2D-IEP against Tamm-Horsfall glycoprotein (1 mg/mL). No precipitin line by IEP against normal human plasma. Identity verified by double immunodiffusion.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Immunogen
Highly purified human Tamm-Horsfall glycoprotein (uromucoid) from urine; >95% pure by SDS-PAGE.
Physical form
In glycine buffered saline, pH 7.4 containing 0.1% sodium azide, 0.1% E-Amino-n-Caproic Acid, 0.01% Benzamidine and 1 mM Ethylenediaminetetraacetic acid as preservatives.
Preparation Note
Maintain at 2-8°C in undiluted aliquots for up to 12 months.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
保管分類
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Brian M Nolen et al.
PloS one, 8(5), e63368-e63368 (2013-06-01)
The analysis of protein biomarkers in urine is expected to lead to advances in a variety of clinical settings. Several characteristics of urine including a low-protein matrix, ease of testing and a demonstrated proteomic stability offer distinct advantages over current
Jean-Claude Kresse et al.
Acta physiologica (Oxford, England), 234(3), e13780-e13780 (2022-01-07)
Renal fibrosis is a major driver of chronic kidney disease, yet current treatment strategies are ineffective in attenuating fibrogenesis. The cyclooxygenase/prostaglandin system plays a key role in renal injury and holds great promise as a therapeutic target. Here, we used
Jenni Karttunen et al.
International journal of molecular sciences, 22(9) (2021-06-03)
Urinary extracellular vesicles (EVs) and their RNA cargo are a novel source of biomarkers for various diseases. We aimed to identify the optimal method for isolating small (<200 nm) EVs from human urine prior to small RNA analysis. EVs from
Fernanda Chacar et al.
Physiological reports, 5(11) (2017-06-04)
Proteinuria is a marker and mediator of chronic kidney disease (CKD). In clinical practice, the urinary protein-to-creatinine ratio (UP/C) is of limited usefulness, because it indicates only the magnitude of proteinuria and not the origin of the loss (glomerular or
Somchai Chutipongtanate et al.
The Journal of clinical investigation, 115(12), 3613-3622 (2005-11-26)
Previous research on proteins that inhibit kidney stone formation has identified a relatively small number of well-characterized inhibitors. Identification of additional stone inhibitors would increase understanding of the pathogenesis and pathophysiology of nephrolithiasis. We have combined conventional biochemical methods with
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）